Statin suppresses the development of excessive intimal proliferation in a Kawasaki disease mouse model
- PMID: 39424429
- PMCID: PMC11489001
- DOI: 10.14814/phy2.70096
Statin suppresses the development of excessive intimal proliferation in a Kawasaki disease mouse model
Abstract
Kawasaki disease (KD) causes vascular injury and lifelong remodeling. Excessive intimal proliferation has been observed, resulting in coronary artery lesions (CALs). However, the mechanisms underlying vascular remodeling in CAL and statin treatment have not been comprehensively elucidated. This study aimed to investigate the effects of statins on vascular remodeling using a KD mouse model. Candida albicans water-soluble substance (CAWS) was intraperitoneally injected in 5-week-old male apolipoprotein-E-deficient mice. They were categorized as follows (n = 4): control, CAWS, CAWS+statin, and late-statin groups. The mice were euthanized at 6 or 10 weeks after injection. Statins (atorvastatin) were initiated after CAWS injection, except for the late-statin group, for which statins were internally administered 6 weeks after injection. Elastica van Gieson staining and immunostaining were performed for evaluation. Statins substantially suppressed the marked neointimal hyperplasia induced by CAWS. Additionally, CAWS induced TGFβ receptor II and MAC-2 expression around the coronary arteries, which was suppressed by the statins. KD-like vasculitis might promote the formation of aneurysm by destroying elastic laminae and inducing vascular stenosis by neointimal proliferation. The anti-inflammatory effects of statins might inhibit neointimal proliferation. Therefore, statin therapy might be effective in adult patients with KD with CAL by inhibiting vascular remodeling.
Keywords: Candida albicans water‐soluble substance; Kawasaki disease; coronary artery lesions; statin; vascular remodeling; vasculitis.
© 2024 The Author(s). Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Ae, R. , Makino, N. , Kosami, K. , Kuwabara, M. , Matsubara, Y. , & Nakamura, Y. (2020). Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: The Nationwide survey in Japan, 2017–2018. The Journal of Pediatrics, 225, 23–29. - PubMed
-
- Amano, S. , Hazama, F. , & Hamashima, Y. (1979). Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Japanese Circulation Journal, 43, 633–643. - PubMed
-
- McCrindle, B. W. , Rowley, A. H. , Newburger, J. W. , Burns, J. C. , Bolger, A. F. , Gewitz, M. , Baker, A. L. , Jackson, M. A. , Takahashi, M. , Shah, P. B. , Kobayashi, T. , Wu, M.‐H. , Saji, T. T. , Pahl, E. , & American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention . (2017). Diagnosis, treatment, and long‐term Management of Kawasaki Disease: A scientific Statement for health professionals from the American Heart Association. Circulation, 135, e927–e999. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
